Quick Answer
Edgewise Therapeutics, Inc. reported Net Income Loss of -$167.80 million for the year ending 2025.
- Edgewise Therapeutics, Inc. showed a decrease of -25.4% in Net Income Loss from 2024 to 2025.
- This data is from Edgewise Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$3.19 million | Q2 2020: -$3.95 million | Q3 2020: -$3.64 million | Q1 2021: -$6.82 million | Q2 2021: -$10.35 million | Q3 2021: -$12.95 million | Q1 2022: -$14.66 million | Q2 2022: -$16.07 million | Q3 2022: -$17.50 million | Q1 2023: -$22.84 million | Q2 2023: -$21.47 million | Q3 2023: -$25.71 million | Q1 2024: -$28.53 million | Q2 2024: -$31.50 million | Q3 2024: -$34.13 million | Q1 2025: -$40.80 million | Q2 2025: -$36.12 million | Q3 2025: -$40.67 million.
- Over the full 6 years of available data (2020 to 2025), Edgewise Therapeutics, Inc.'s Net Income Loss has declined by 879.9%.
- Historical annual values: Fiscal year 2025: -$167.80 million | Fiscal year 2024: -$133.81 million | Fiscal year 2023: -$100.16 million | Fiscal year 2022: -$67.64 million | Fiscal year 2021: -$42.81 million | Fiscal year 2020: -$17.12 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: